Gregory Yanik
University of Michigan · University of Michigan Rogel Cancer Center · University of Michigan Comprehesive Cancer Ctr
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gregory Yanik as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:51 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05866302 · Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant RecipientsUniversity of Michigan Rogel Cancer Center · recruiting · Chronic Lung Disease, Hematopoietic Cell Transplantation, Graft Versus Host Disease · principal investigator
- Ph1NCT04530604 · Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)Gregory Yanik · completed · COVID, Sars-CoV2, COVID-19 · principal investigator
- Ph2NCT00639717 · Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell TransplantUniversity of Michigan Rogel Cancer Center · completed · Graft Versus Host Disease · principal investigator
- Ph2NCT00623935 · Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous LeukemiaUniversity of Michigan Rogel Cancer Center · completed · Acute Myelogenous Leukemia · principal investigator
- Ph2NCT00309907 · Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell TransplantChildren's Oncology Group · completed · Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission · principal investigator
- Ph2NCT00253435 · N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk NeuroblastomaNew Approaches to Neuroblastoma Therapy Consortium · completed · Neuroblastoma · study chair
- Ph1NCT00083135 · N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell TransplantationNew Approaches to Neuroblastoma Therapy Consortium · completed · Neuroblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- BMT Core- University of Michigan Core Clinical Consortium for the BMT Clinical Trials Network (BMT CTN)UG1HL069330 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2017 to 2025 · $226,361 awarded in 2025Same name and institution; not confirmed by an ID
- Parametric Response Mapping (PRM) for the detection of chronic lung injury in hematopoietic cell transplant recipientsR01HL162661 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2022 to 2025 · $741,498 awarded in 2025Grant number is on one of their registry trials
- University of Michigan Core Clinical Center for BMT Research NetworkU10HL069330 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2015 to 2016 · $160,943 awarded in 2016Same name and institution; not confirmed by an ID
- ETANERCEPT FOR TREATMENT OF SUB-ACUTE PULM DYSFUNCTION AFTER ALLOGENEIC BMTM01RR000042 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2004 to 2007 · $5,650 awarded in 2007Same name and institution; not confirmed by an ID
- MIBG Plus Intensive Chemotherapy for NeuroblastomaR01FD002189 · FDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2005 · $351,289 awarded in 2005Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Children's Oncology Group Chair's GrantU10CA098543 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI PETER C. ADAMSON · fiscal years 2003 to 2013Named on NCT00309907
- NATURAL KILLER CELL BASED IMMUNOTHERAPYP01CA081403 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI ROBERT Charles SEEGER · fiscal years 2000 to 2014Named on NCT00253435, NCT00083135
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:51 UTC. The ranking covers the 200 most relevant of 52 PubMed records, and a shared surname and initials can bring in a namesake. All 52 on PubMed
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med · 20184,679 citationsRCR 163.2
- Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.J Clin Oncol · 2023345 citationsRCR 28.7
- Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.Cancer Res · 2001278 citationsRCR 5.3
- Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.J Clin Oncol · 2021231 citationsRCR 14.2
- Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.J Clin Oncol · 2007188 citationsRCR 4.8
- 137 citationsRCR 3.5
- Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy.Radiology · 1996112 citationsRCR 4.6
- 108 citationsRCR 3.0
- α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.Blood · 2018106 citationsRCR 4.5
- Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.J Clin Oncol · 200298 citationsRCR 2.4